COVID-19 Archives - Page 6 of 16

Executive Moves

RNADD adds renowned pro sports team physician Michael Farber to advisory board

Michael Farber Closely-held RNA Disease Diagnostics appointed board-certified internist and professional sports physician, Michael Farber, M.D., to its advisory board. Dr. Farber is the medical director of executive...

September 2, 2021

Developments

PharmaJet needle free system cleared for first plasmid DNA COVID-19 vaccine

Closely-held PharmaJet announced that its partner, Zydus Cadila, has received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world’s first plasmid DNA vaccine for...

August 23, 2021

Markets

WB starts Icosavax at outperform

William Blair launched coverage of Icosavax (NASDAQ:ICVX) with an “outperform” rating. The stock closed at $34.09 on Aug. 20. “We believe Icosavax stands to benefit from both the medical and investment communities’...

August 23, 2021

Markets

BTIG starts CTI Biopharma at buy; PT $7

BTIG initiated coverage of CTI Biopharma (NASDAQ:CTIC) with a “buy” rating and price target of $7. The stock closed at $2.80 on Aug. 6. CTI is a biotechnology company engaged in the development of therapeutics for blood...

August 9, 2021

Developments

ENA Respiratory begins Phase 1 study of COVID-19 preventative nasal spray

Closely-held ENA Respiratory of Australia initiated a Phase 1 human safety study of INNA-051, being developed to activate innate immunity in the nose, the primary entry portal of most respiratory viral infections. ...

July 14, 2021

Executive Moves

Healthcare veteran Richard Ganz joins RNA Disease Diagnostics board

Closely-held RNA Disease Diagnostics appointed Robert Ganz, a healthcare veteran with more than 40 years of executive experience in venture-backed startups and international healthcare companies, to the board. Mr. Ganz...

July 8, 2021

Developments

Lumos Diagnostics raises $63-million (Australian) in IPO

Lumos Diagnostics, with corporate head offices in Melbourne and U.S.-based R&D, commercial operations and manufacturing in both Florida and California, raised $63-million (Australian) in an initial public...

July 8, 2021

Markets

Cantor starts Arcturus Therapeutics at OW; PT $71

Cantor Fitzgerald launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with an “overweight” rating and $71 price target. The stock closed at $35.94 on July 1. Arcturus is leveraging its proprietary lipid-based...

July 2, 2021

Executive Moves

PharmaJet names Paul LaBarre as VP global business development

Paul LaBarre PharmaJet named Paul LaBarre as VP of global business development to lead business development and commercialization strategies, replacing Melissa Malhame, who transitioned to a strategic advisory role for...

June 15, 2021

Developments

U of Maryland School of Medicine lab approved as development site for RNA Disease Diagnostics COVID-19 test

The FDA registered the laboratory of Dipanjan Pan, Ph.D., at the University of Maryland School of Medicine, as an approved laboratory development site for RNA Disease Diagnostics’ (RNADD) Antisense COVID-19 molecular...

June 3, 2021

Tag - COVID-19

RNADD adds renowned pro sports team physician Michael Farber to advisory board

PharmaJet needle free system cleared for first plasmid DNA COVID-19 vaccine

WB starts Icosavax at outperform

BTIG starts CTI Biopharma at buy; PT $7

ENA Respiratory begins Phase 1 study of COVID-19 preventative nasal spray

Healthcare veteran Richard Ganz joins RNA Disease Diagnostics board

Lumos Diagnostics raises $63-million (Australian) in IPO

Cantor starts Arcturus Therapeutics at OW; PT $71

PharmaJet names Paul LaBarre as VP global business development

U of Maryland School of Medicine lab approved as development site for RNA Disease Diagnostics COVID-19 test

Subscribe